Skip to main content
Premium Trial:

Request an Annual Quote

Pathwork Diagnostics Closes on $30M Series C Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Pathwork Diagnostics today announced it has closed its $30 million Series C financing.

The round was led by Alta Partners and included existing investors Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners, and Venrock. David Mack, a director at Alta Partners, has joined the board of Pathwork, the Redwood City, Calif., company said in a statement.

According to Pathwork CEO Deborah Neff, the round "provides the resources to support our commercial activities and expand our product offerings."

The company offers its Tissue of Origin Test for identifying the source of cancers that are difficult to classify. The test, which received FDA clearance in June, works on formalin-fixed paraffin embedded tissue and increases an oncologists' confidence in their choice of treatment, Pathwork said.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.